Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArdelyxARDX -1.08%70 Debt-to-Equity is 1.40 as of Mar. 2026, which is 150% above its 10-year median of 0.56. GuruFocus rates ARDX with a GF Score™ of 70/100 and a GF Value™ of $10.42 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 965 Biotechnology companies, Ardelyx ranks worse than 90.47% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Ardelyx's Debt-to-Equity or its related term are showing as below:
ARDX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.18 Med: 0.56 Max: 1.48
Current: 1.4
During the past 13 years, the highest Debt-to-Equity Ratio of Ardelyx was 1.48. The lowest was 0.18. And the median was 0.56.
ARDX's Debt-to-Equity is ranked worse than 90.47% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs ARDX: 1.40
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Ardelyx Debt-to-Equity Related Terms
Ardelyx Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Ardelyx's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARDX vs IMTX, TRAX, AVLN: Debt-to-Equity Comparison
For the Biotechnology subindustry, Ardelyx's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ardelyx Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ardelyx's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Ardelyx's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ardelyx (ARDX) has a Debt-to-Equity of 1.40 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ardelyx and its competitors. This is 150% above median its historical median of 0.56. Over the past decade, Ardelyx's Debt-to-Equity has ranged from 0.18 to 1.48. According to the industry distribution chart, Ardelyx ranks #873 out of 965 companies in the Biotechnology industry, placing it in the top 90.5%.
Is Ardelyx's Debt-to-Equity too high?
Ardelyx's current Debt-to-Equity of 1.40 is 150% above median its 10-year median of 0.56. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 1.48. The Biotechnology industry median Debt-to-Equity is 0.16. Ardelyx's value of 1.40 is 775% above this industry median. Based on the distribution chart, Ardelyx ranks #873 out of 965 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ardelyx has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ardelyx's Debt-to-Equity compare to IMTX and TRAX?
According to the Biotechnology industry distribution chart, Ardelyx ranks #873 out of 965 companies for Debt-to-Equity. This places Ardelyx in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Ardelyx's value of 1.40 is 775% above this benchmark. Historically, Ardelyx's own Debt-to-Equity has ranged from 0.18 to 1.48 over the past decade. While the company's 10-year median is 0.56 vs. the industry median of 0.16, Ardelyx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ardelyx's current Debt-to-Equity of 1.40 is 775% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ardelyx and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ardelyx's current Debt-to-Equity is 1.40, which is 150% above median its own 10-year median of 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ardelyx stock overvalued right now?
Based on GuruFocus' analysis, Ardelyx (ARDX) is currently considered Possible Value Trap. The stock's GF Value™ is $10.42, compared to a current price of $5.04 — trading 51.7% below its estimated fair value. The current Debt-to-Equity is 1.40, which is 150% above median its 10-year median of 0.56 and 775% above the Biotechnology industry median of 0.16. Ardelyx's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Ardelyx (ARDX), the current Debt-to-Equity is 1.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ardelyx (ARDX) Overvalued in 2026?
Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued.
The current stock price of $5.04 is trading 51.7% below its estimated GF Value™ of $10.42.
GuruFocus considers Ardelyx to be Possible Value Trap.
Key valuation signals for ARDX:
Debt-to-Equity: 1.40 (150% above median its 10-year median of 0.56)
GF Value™: $10.42 vs. price of $5.04 (51.7% below fair value)
Industry Position: 775% above the Biotechnology median (#873 of 965)
No single metric tells the full story. See the ARDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
70GF Score
Get the complete analysis for ARDX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARDX has been successfully added to your 
